Eli Lilly and Company

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Retrieved on: 
Monday, January 8, 2024
Commercial, Boehringer Ingelheim, DNA, Cancer, Investment, Novartis, SVP, Fermentation, Beam, Atlas, Kite Pharma, RNA interference, Sensible, Drug discovery, AbbVie, Invention, Biotechnology Innovation Organization, Eli Lilly, MBA, HIV, Merck, Therapy, Creativity, Epidemiology, RNA, GSK plc, DARPA, Process, WARF, Johnson & Johnson, Movement, Ginkgo Bioworks, Novo Nordisk, AI, Atlas Venture, AAV, Patient, Medicine, Synthetic biology, Senior, M28, Acquisition, BIO, MD, Doctor of Philosophy, Eli Lilly and Company, Hematology, Growth, Avantor, Infection, Pharmaceutical industry

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.

Key Points: 
  • BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
  • "The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks.
  • Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

UpDoc Debuts the World's First AI Assistant That Manages Medication Prescriptions and Chronic Conditions

Retrieved on: 
Friday, January 5, 2024
Cloud, Patient, Azure, Google Cloud, Stanford University, Doctor of Pharmacy, Microsoft, RPI, UCSF Medical Center, Health care, American Heart Association, Physician, Research, Health literacy, Microsoft Band, Conditional sentence, Diabetes, Health, MD, Prescription, Medicine, Health equity, Polaris Partners, Standard of care, Eli Lilly and Company, Remote patient monitoring, RPM, Perception, Mayo Clinic, JAMA Network Open, Stanford University Medical Center, Organization, Corporation, Medical device

UpDoc aims to deliver a clinician-directed AI provider to every patient's home through accessible technology that improves access to high quality, affordable care.

Key Points: 
  • UpDoc aims to deliver a clinician-directed AI provider to every patient's home through accessible technology that improves access to high quality, affordable care.
  • All care delivered through the AI is prescribed by physicians or clinical pharmacists who oversee the platform.
  • By scaling provider reach, the AI assistant is also designed to improve efficiency and reduce clinical burnout.
  • We are eager to see what opportunities AI can offer in helping patients make sense of their medications and better manage their health."

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

Retrieved on: 
Friday, January 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biology, Conference, Family, Partnership, Drug discovery, Metabolism, WRN, IND, Drug design, Werner syndrome helicase, Pain scale, MBA, Therapy, Eli Lilly and Company, HPK1, DSM-IV codes, AMPK, Investment, Patient, TYK2, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
  • "Building on the success of our TYK2 program, we are broadening our drug discovery engine to unlock new difficult-to-drug targets with compelling biology,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus.
  • “SIK and cGAS are critical targets in highly prevalent diseases that are well suited to Nimbus’ structure-based drug design approach.
  • Nimbus continues to expand its platform capabilities with ongoing investments in cutting-edge technology for drug discovery.

The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya

Retrieved on: 
Thursday, January 4, 2024
Novartis, Cepheid variable, Lilly, Partner, ABC, HER2, Death, Woman, Breast cancer, Developed country, HR, Access, Environment, Society, Health equity, Cancer, Health, Eli Lilly and Company, PACT, Knowledge, Pathology, Patient, Medicine, Palliative care, Pharmaceutical industry

"We are thrilled to have Lilly join as a Humanitarian PACT partner to expand access to treatment for people living with advanced breast cancer," said Pat Garcia-Gonzalez, Co-founder, and CEO of The Max Foundation.

Key Points: 
  • "We are thrilled to have Lilly join as a Humanitarian PACT partner to expand access to treatment for people living with advanced breast cancer," said Pat Garcia-Gonzalez, Co-founder, and CEO of The Max Foundation.
  • "This donation of Verzenio to help advanced breast cancer patients in Kenya reflects our continued effort to improve access to healthcare for people living in limited-resource settings."
  • Partners in the Humanitarian PACT for ABC have agreed to invest resources and/or their unique knowledge and capabilities to support the expansion of Max Access Solutions to provide access to treatment for HR+/HER2- advanced breast cancer.
  • Late last year, through donation of medicine from Novartis AG, Mozambique became the first country to receive treatment access.

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

Retrieved on: 
Thursday, January 4, 2024
Eli Lilly and Company, LLY, Obesity, Patient, Hope, Health, Diabetes, Migraine, Conditional sentence, Pharmaceutical industry

INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.

Key Points: 
  • INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
  • LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
  • "LillyDirect offers more choices in how and where people access healthcare, including a convenient home delivery option to fill Lilly medicines they have been prescribed."
  • For patients living with obesity, migraine and diabetes, LillyDirect offers:
    LillyDirect Pharmacy Solutions, a digital pharmacy for select Lilly medicines powered by third party online pharmacy fulfillment services.

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases

Retrieved on: 
Thursday, January 4, 2024
Lilly, Immunology, Metabolism, Immune system, Autoimmunity, Inflammation, Trial of the century, Therapy, Eli Lilly and Company, GSK, Medicine, Sofinnova, Senior, Pharmaceutical industry

Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.

Key Points: 
  • Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
  • Lilly is leading further development and potential commercialization of the Phase 1 immunometabolism-targeting therapy.
  • Sitryx and Lilly entered into an exclusive global licensing and research collaboration agreement in March 2020 , under which Sitryx received an upfront payment of $50 million and Lilly made a $10 million equity investment in the Company.
  • Sitryx is using the proceeds to advance its proprietary pipeline of immunometabolism-targeting therapies into clinical development.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Kite Pharma, Engineering management, Tufts University, Marketing, Lilly, Migraine, Johnson & Johnson, Amgen, Sale, AstraZeneca, Daiichi Sankyo, Eli Lilly, Jan Vansina, Business administration, Engineering, WebMD, MBA, Chemical engineering, Doctor of Philosophy, Roivant Sciences, Therapy, Eli Lilly and Company, Consumer service, University, Washington State University, Worcester Polytechnic Institute, Iowa State University, SVP, Corporation, Pharmaceutical industry

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

Key Points: 
  • ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
  • “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
  • Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.

Lilly to Participate in J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Eli Lilly and Company, LLY, Conference

INDIANAPOLIS, Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024.
  • David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 30 days.